Rethinking the bioethical enactment of medically drugged bodies: Paradoxes of using anti-HIV drug therapy as a technology for prevention

Science as Culture

Volumn 18, Issue 2, 2009, Pages 183-199

  Rosengarten, Marsha ^a   Michael, Mike ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bioethics; Clinical trials; Drugs; HIV; Multiple ontologies; Pre exposure prophylaxis (PrEP)

Indexed keywords

EID: 84861652366     PISSN: 09505431     EISSN: 14701189     Source Type: Journal    
DOI: 10.1080/09505430902885565     Document Type: Article

References (49)

1. AVAC (AIDS Vaccine Advocacy Coalition). 2005. Will a Pill a Day Prevent HIV? Anticipating the Results of ‘PREP’ Trials, New York:AVAC.
2. AVAC (AIDS Vaccine Advocacy Coalition). 2007. Summary Report of the December 12, 2007 Meeting of the AIDS Vaccine Research Subcommittee, New York:AVAC.
3. AVAC (AIDS Vaccine Advocacy Coalition) (2008) Anticipating the Results of PrEP Trials:A Powerful New HIV Prevention Tool may be on the Horizon. Are we Prepared? A publication from AVAC's Anticipating and Understanding Results series.
4. Bass, E., and Kahn, P., 2005. “ Testing AIDS vaccines in people ”. In AIDS Vaccine Handbook:Global Perspectives, 2, Edited by:Kahn, P., New York:AVAC.
5. Benatar, S. R., 2004. Linking moral progress to medical progress:new opportunities for the Declaration of Helsinki. Journal of the World Medical Association, 50 (1) March:11–13.
6. Biagioli, M., 1992. “ Science, modernity and ‘the final solution’ ”. In Probing the Limits of Representation, Edited by:Friedlander, S., Cambridge, MA:Harvard University Press.
7. Birke, L., Arluke, A., and Michael, M., 2007. The Sacrifice:How Scientific Experiments Transform Animals and People, West Lafayette, IN:Purdue University Press.
8. Cartwright, N., 2007. Are RCTs gold standard?. Biosocieties, 2:11–20.
9. Cassell, M. M., Halperin, D. T., Shelton, J. D., and Stanton, D., 2006. Risk compensation:the Achilles' heel of innovations in HIV prevention?. British Medical Journal, 332:605–607.
10. Chaya, N., 2006. Cambodia and HIV:winning round two in a preventive fight, Research Commentary. Population Action International, 1 (7) July Available at:www.populationaction.org
11. De Laet, M., and Mol, A., 2000. The Zimbabwe bush pump. Mechanics of a fluid technology. Social Studies of Science, 30 (2):225–263.
12. Epstein, S., 1996. Impure Science, Berkeley, CA:University of California Press.
13. Ghosn, J., Viard, J., Katlama, C., de Almeida, M., Tubiana, R., Letourneur, F., Aaron, L., Giele, C. M., Maw, R., Carne, C. A., and Evans, B. G., On behalf of the British co-operative clinical group of the Medical Society for the Study of Venereal Diseases (2002) Post-exposure prophylaxis for non-occupational exposure to HIV:current clinical practice and opinions in the UK. Sexually Transmitted Infections, 78 (2) April:130–132.
14. Grant, R. M., Buchbinder, S., Cates, W., Clarke, E., Coates, T., Cohen, M. S., Delaney, M., Flores, G., Goicochea, P., Gonsalves, G., Harrington, M., Lama, J. R., MacQueen, K. M., Moore, J. P., Peterson, L., Sanchez, J., Thompson, M., and Wainberg, M. A., 2005. AIDS:promote HIV chemoprophylaxis research, don't prevent it. Science, 30 September:2170–2171.
15. Harding, S., 1991. Whose Science? Whose Knowledge? Thinking from Women's Lives, Ithaca, NY:Cornell University Press.
16. Horwood, J., 2007. Cellulose sulphate microbicide trial halted. The Lancet Infectious Diseases, 7 (3):183
17. Human Rights Watch and Thai AIDS Treatment Action Group. 2007. Deadly Denial:Barriers to HIV/AIDS Treatment for People Who Use Drugs in Thailand, 19 (17) November
18. IAS (International AIDS Society). 2005. Building Collaboration to Advance HIV Prevention. Global Consultation on Tenofovir Pre-Exposure Prophylaxis Research, US National Institutes of Health and US Centers for Disease Control and PreventionSeptember. Report of a Consultation Convened by the International Aids Society on Behalf of the Bill and Melinda Gates Foundation
19. Irwin, A., and Michael, M., 2003. Science, Social Theory and Public Knowledge, Maidenhead, Berks:Open University Press/McGraw-Hill.
20. Jintarkanon, S., Nakapiew, S., Tienudom, N., Suwannawong, P., and Wilson, D., 2005. Unethical clinical trials in Thailand:a community response. Lancet, 365:1617–1618.
21. Kahn, P., 2005. “ AVAC report adapted, vaccine trials:leaving communities better off ”. In AIDS Vaccine Handbook:Global Perspectives, 2, Edited by:Kahn, P., New York:AVAC.
22. MacQueen, K. M., Namey, E., Chilongozi, D. A., Mtweve, S. P., Mlingo, M., Morar, N., Reid, C., Ristow, A., Sahay, S., and HPTN 035 Standard of Care Assessment Team. 2007. Community perspectives on care options for HIV prevention trial participants. AIDS Care, 19 (4):554–560.
23. Mansky, L. M. 2002. HIV mutagenesis and the evolution of antiretroviral drug resistance. Drug Resistance Updates, 5 (6) December:219–223.
24. Mayer, K. H., Maslankowski, L. A., Gai, F., El-Sadr, W. M., Justman, J., Kwiecien, A., Masse, B., Eshleman, S. H., Hendrix, C., Morrow, K., Rooney, J. F., Soto-Torres, L., and the HPTN 050 Protocol Team. 2006. Safety and tolerability of Tenofovir vaginal gel in abstinent and sexually active HIV-uninfected and infected women. AIDS, 20 (4):543–551.
25. Mills, E., Nixon, S., Singh, S., Dolma, S., Nayyar, A., and Kapoor, S., 2006. Enrolling women into HIV preventive vaccine trials:an ethical imperative but a logistical challenge. PLoS Medicine, 3 (3) March:1–4. e94
26. Mills, E., Rachlis, B., Wu, P., Wong, E., Wilson, K., and Singh, S., 2005a. Media reporting of Tenofovir trials in Cambodia and Cameroon. BMC International Health and Human Rights, 5 (6):1–7.
27. Mills, E. J., Sing, S., Sing, J. A., Orbinski, J. J., Warren, M., and Upshur, R. E., 2005b. Designing research in vulnerable populations:lessons from HIV prevention trials that stopped early. British Medical Journal, 331:1404
28. Mol, A., 2003. The Body Multiple:Ontology in Medical Practice, Durham, NC:Duke University Press.
29. Moodley, K., 2007. Microbicide research in developing countries:have we given the ethical concerns due consideration?. BMC Medical Ethics, 8 (10):3–7.
30. Page-Shafer, K., Saphonn, V., Penh Sun, L., Chhi Vun, M., Cooper, D. A., and Kaldor, J. M., 2005. HIV prevention research in a resource-limited setting:the experience of planning a trial in Cambodia. The Lancet, 366:1499–1503.
31. Paxton, L. A., Hope, T., and Jaffe, H. W., 2007. Pre-exposure prophylaxis for HIV infection:what if it works?. Lancet, 370:89–93.
32. Petryna, A., 2007. Clinical trials offshored:on private sector science and public health. BioSocieties, 2:21–40.
33. Proctor, R., 1989. Racial Hygiene, Cambridge, MA:Harvard University Press.
34. Richens, J., Edwards, S. G., and Sadiq, S. T., 2005. Can the promotion of post-exposure prophylaxis following sexual exposure to HIV (PEPSE) cause harm?. Sexually Transmitted Infections, 81:190–191.
35. Robertson, M., Mehrotra, D., Fitzgerald, D., Duerr, A., Casimiro, D. R., Mcelrath, J., Lawrence, D., and Buchbinder, S., 2008. “ Efficacy results from the STEP Study (Merck V520 protocol 023/HVTN 502):a phase II test-of-concept trial of the MRKad5 HIV-1 gag/pol/nef trivalent vaccine ”. In Fifteenth Conference on Retroviruses and Opportunistic Infections Boston Abstract 88LB, 2008
36. Rosengarten, M., and Michael, M., 2009. “ HIV:pre-exposure prophylaxis or PrEP and the complexities of biomedical prevention ”. In HIV, Technology and Subjectivity:International Cases Studies of HIV Treatment and Prevention, Edited by:Davis, M. D. M., and Squire, C., New York:Palgrave.
37. Shapiro, H. T., and Meslin, E. M., 2001. Ethical issues in the design and conduct of clinical trials in developing countries. New England Journal of Medicine, 345 (2):139–142.
38. Singh, J. A., and Mills, E. J., 2005. The abandoned trials of pre-exposure prophylaxis for HIV:what went wrong?. PLoS Medicine, 2 (9):0001–0004. e234
39. Stephenson, J., 2008. HIV prevention studies yield mixed results. Journal of the American Medical Association, 299 (13):1529–1530.
40. The Thai AIDS Treatment Action Group (TTATAG) (2004) Letter, 8 December. Available at:http://www.aidsinfonyc.org/tag/activism/thaiTenofovir.html
41. UNAIDS. 2006. Creating effective partnerships for HIV prevention trials:report of the UNAIDS consultation, Geneva, 20–21 June 2005. AIDS, 20:W1–W11.
42. UNAIDS. 2007. Fact Sheet AIDS Epidemic Update—Regional Summary Available at:http://data.unaids.org/pub/FactSheet/2008/epi07_fs_regionalsummary_asia_en.pdf (accessed April 2008)
43. UNAIDS and AVAC. 2007. Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials 18 May, draft report
44. Van de Ven, P., Crawford, J., Kippax, S., Knox, S., and Prestage, G., 2000. A scale of optimism–scepticism in the context of HIV treatments. AIDS Care, 12:171–176.
45. Weijer, C., and LeBlanc, G., 2005. “ Revisiting the ethics of HIV prevention research in developing countries ”. UNAIDS background paper, 7 June
46. WHO (World Health Organisation) (2007) Available at:http://www.who.int/hiv/pub/guidelines/pmtct/en/index.html (accessed 2007).
47. WHO (World Health Organisation). 2007. Cellulose Sulfate Microbicide Trial Stopped Available at:http://www.who.int/mediacentre/news/statements/2007/s01/en/ (accessed 29 April 2008)
48. WHO/UNAIDS. 2004. Treating people with intercurrent infection in HIV prevention trials. AIDS, 18 (15) 21 October:W1–12. Report from a WHO/UNAIDS consultation, Geneva, 17–18 July 2003 p. 1
49. Women's Network for Unity (WNU). 2004. Protests Drug Trial Recruitment Tactics, Public statement released by WNU Secretariat. 15 June